Medical and Dental Consultantsí Association of Nigeria
Home - About us - Editorial board - Search - Ahead of print - Current issue - Archives - Submit article - Instructions - Subscribe - Advertise - Contacts - Login 
  Users Online: 370   Home Print this page Email this page Small font sizeDefault font sizeIncrease font size
 

  Table of Contents 
ORIGINAL ARTICLE
Year : 2020  |  Volume : 23  |  Issue : 12  |  Page : 1683-1689

Clinical Outcomes of Nasopharyngeal Carcinoma Patients Treated with Adaptive Helical Tomotherapy, A 5-year Experience


Department of Radiation Oncology, Ankara City Hospital, Yildirim Beyazit University School of Medicine, Ankara, Turkey

Date of Submission29-Nov-2019
Date of Acceptance06-Jul-2020
Date of Web Publication23-Dec-2020

Correspondence Address:
Dr. S A Arslan
Universiteler mah. Bilkent Cad. No.: 1, 06100 Cankaya, Ankara
Turkey
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/njcp.njcp_647_19

Rights and Permissions
   Abstract 


Objectives: The study aims to retrospectively review the survival and toxicity outcomes of adaptive helical tomotherapy (HT) treatment of nasopharyngeal carcinoma (NPC) patients over 5 years. Methods: Between February 2010 and September 2017, 67 biopsy-proven non-metastatic NPC patients were analyzed. All patients except one received concurrent chemotherapy and treated with adaptive Simultaneous integrated boost- intensity-modulated radiation therapy (SIB-IMRT). The median age was 48.5 years (range, min: 11 max: 78) with male predominance (82.1% vs. 17.9%). Neck mass was the most common presenting symptom followed by hearing problems (52% and 24%). Results: The mean dose with standard deviation (sd) of D50 to patients' parotid glands and cochleae were 33 ± 11 Gy; 31 ± 11 9 Gy and 37 ± 11 14 Gy; 34 ± 11 14 Gy, respectively. Locoregional progression-free survival (LRRFS), disease-free survival (DFS), distant metastasis-free survival (DMFS), and overall survival (OS) estimated at 2 and 5 years were 83% and 63%, 78.4% and 61.7%, 83% and 69%, 86% and 71%, respectively. Acute Grade 3 or higher dysphagia and mucositis observed in 28 (42%) patients who required daily iv fluid transfusion and/or hyperalimentation. None of the patients had grade 3 and higher mucous membranes and salivary gland toxicity beyond 6 months. Two patients had ≥ grade 3 late toxicity. During the median 51 months (range 2–100) follow up, thirteen patients relapsed (19.4%), six of them (8.9%) recurred locoregionally, and 7 (10.4%) of them developed distant metastasis. Conclusion: The present study reemphasizes that adaptive SIB-IMRT with HT is a good option for the management of NPC with comparable loco-regional control rates and low salivary gland toxicity.

Keywords: Adaptive intensity-modulated radiotherapy, helical tomotherapy, nasopharyngeal carcinoma, simultaneous integrated boost


How to cite this article:
Arslan S A. Clinical Outcomes of Nasopharyngeal Carcinoma Patients Treated with Adaptive Helical Tomotherapy, A 5-year Experience. Niger J Clin Pract 2020;23:1683-9

How to cite this URL:
Arslan S A. Clinical Outcomes of Nasopharyngeal Carcinoma Patients Treated with Adaptive Helical Tomotherapy, A 5-year Experience. Niger J Clin Pract [serial online] 2020 [cited 2022 Nov 30];23:1683-9. Available from: https://www.njcponline.com/text.asp?2020/23/12/1683/304433




   Introduction Top


Nasopharyngeal carcinoma (NPC) is a unique head and neck malignancy arising from the epithelium of nasopharynx and accounts up to 0.7/100.000 worldwide in 2018 with an approximately 2- to 3-fold male predominance.[1] Significant variation exists between different geographical regions, Turkey, though being in the middle of two continents Asia and Europa have an incidence of 0.4 to 1.2 per 100 000 for females and males increasing after age 40.[2] Concurrent chemoradiotherapy (CRT) is the main curative approach for loco-regional disease, excluding early node-negative state (T1N0).[3] The nasopharyngeal region is adjacent to highly delicate organs such as the brainstem, optic nerves, salivary glands, and swallowing muscles, which necessitates highly conformal radiation planning. Intensity-modulated radiotherapy (IMRT) is the standard treatment of choice for NPC in terms of dose homogeneity and sparing of critical structures, which can lead to improved local control and reduced side effects.[4],[5]

Tomotherapy is a unique way of applying IMRT with the ability of megavoltage computed tomography (MVCT) image guidance to eliminate inter-fractional variations. Simultaneous integrated boost (SIB) technique allows different dosing for tumor and risky subclinical areas with one inverse planning.[6],[7] This method of IMRT has been clinically confirmed as safe and effective and eventually became the predominant mode of radiation delivered with improved dose distributions.[8] Increased fraction dose (2,12-2.4 Gy) to the tumor site and shortening overall treatment time can provide better local control by reducing accelerated repopulation of tumor cells.[9]

Adaptive RT is defined as the modification of the radiation treatment plan delivered to a patient during therapy to account for temporal changes in anatomy for example, tumor shrinkage or weight loss. It reoptimizes the treatment to avoid unnecessary doses received by critical structures such as parotid glands and reduces the risk of xerostomia.[10]

This study aims to present 5-year clinical outcomes of 67 non-metastatic NPC patients treated with adaptive SIB-IMRT technique in our helical tomotherapy (HT) unit.


   Materials and Methods Top


Patients: Between February 2010 and September 2017, 67 pathologically confirmed, non-metastatic NPC patients treated in a tertiary radiation oncology clinic HT unit, Ankara, Turkey were retrospectively reviewed upon approval of an ethical board. Informed consent was taken before treatment. Patient files and hospital electronic information systems were used for data collection. Direct phone calls were done when needed. All patients had detailed Head & Neck examinations, including the endoscopic evaluation and their biopsy taken either from neck nodes or nasopharynx. All patients had pretreatment magnetic resonance imaging (MRI) of nasopharynx and neck and staged mostly using Positron emission tomography-computed tomography (PET-CT) (n = 62, 92.5%) according to the tumor node metastasis (TNM)eighth staging system.

RT planning: Patients were immobilized with a thermoplastic head and shoulder mask, and a ≤3-mm slice thickness of plain computerized tomography (CT) images were taken before treatment. IV contrast was used according to treating physician desire. Primary and nodal gross tumor volumes (GTVs) were delineated with the guidance of MRI and PET-CT fusion of simulation CT images. GTVs were expanded 5 mm isotropically to form clinical target volume 70 (CTV70), and CTV70 was expanded 3 mm to form a planning target volume of 70 Gy (PTV70). The margin between GTV to CTV can be reduced to 1 mm in adjacent critical normal structures such as the brainstem. High-risk clinical target volume of 60 Gy (CTV60) encompasses a 5- mm isotropic expansion of PTV70 and the areas at risk for microscopic involvement including whole nasopharynx, inferior sphenoid sinus, posterior parts of paranasal sinuses, base of skull, clivus, pterygoid fossa and high risk nodal levels bilaterally (retropharyngeal nodes, neck node levels 2, 3,4 absolutely, 1b if level 2 is involved, 5 if level 2, 3, 4 are involved). Low-risk clinical target volume of 56 (CTV56) includes the upper part of sphenoid sinus if not involved and clinical negative neck node levels 4 and 5 bilaterally. CTVs were rearranged with the exclusion of bone, air and then expanded with a 3-mm isotropic margin to form corresponding PTV60 and PTV56. PTVs were cropped 2-mm from the skin unless suspicion of dermal lymphatic layer invasion. Bilateral orbits, optic nerves, chiasma, brainstem, cochlea, temporomandibular joints, spinal cord, parotid glands, oral cavity, and esophagus were contoured as organs at risk (OAR).

For PTV70, PTV60, and PTV56, the planning dose at D95 was prescribed to 70 Gy (2.12 Gy/fx), 59.4 Gy (1.8 Gy/fx), and 56 Gy (1.7 Gy/fx) respectively in 33 fractions. Subtraction PTV volumes generated for optimization purposes. Planning parameters were: Field width (FW) = 2.5 cm, pitch = 0.215 and modulation factor (MF) = 2-3. No more than 1% of PTV volume received more than 108% of the prescribed dose. Institutional dose-volume constraints for OARs were as follows: Brainstem 1 cc <59 Gy, extended cord Dmax <45 Gy, parotid gland Dmean <25 Gy for node-negative neck site; V30 <50% for node-positive site, oral cavity beyond PTV <30 Gy. Image guidance was performed before each fraction; MVCT images of treatment area were taken, fused, and registered with both bony and tissue anatomy, whichever best fits PTVs and OARs. RT was delivered once daily, 5 days a week.

Patients except for T1N0 offered weekly 40 mg/m2 cisplatin concomitantly and 3 cycles of adjuvant cisplatin and fluorouracil (CF) chemotherapy unless received induction chemotherapy (Carboplatin instead of cisplatin if there is renal impairment).

During RT, patients were monitored by the same treating physician (the same radiation oncologist did treatment plans and follow-ups during radiotherapy) for acute side effects, especially mucositis and dysphagia on weekly bases. Preliminary response assessment was done by Ear Nose Throat (ENT) specialist with a full head&neck examination, including fiberoptics imaging of nasopharynx (NP) one month after and with PET-CT 3 to 4 months after the end of RT unless suspect about disease dissemination. Follow-up was conducted every 3 months for the first 2-year and subsequently every 6 months for the following 3 years and yearly after that. During follow-up examinations, patients were evaluated for long-term side effects and any type of recurrence. Acute and late toxicities were scored according to the Radiation Therapy Oncology Group (RTOG) and the European Organization of Research and Treatment of Cancer (EORTC) toxicity criteria.[11]

SPSS v20 was used for statistical analyses. Kaplan Meier method estimated loco-regional relapse-free survival (LRRFS), disease-free survival (DFS), distant metastasis-free survival (DMFS), and overall survival (OS). Loco-regional relapse-free survival was defined as the time between pathologic diagnosis of NPC and local or regional recurrence, death due to NPC, or unknown causes with the undocumented site of failure. Similarly, the event of interest was any type of recurrence (local, regional, distant) or death from any cause for DFS, distant metastasis or death for DMFS, death from any cause for OS. P value ≤0.05 was considered significant.


   Results Top


Pathologically confirmed staged 1-4 NPC patients treated in our HT unit were retrospectively reviewed. All patients except one completed the planned RT. Patients with distant metastasis at the time of diagnosis were excluded. The median age at diagnosis was 48.5 years (11–78) with male predominance (n = 54, 81.8%). The median age for female and male were 38 (IQR = 18) and 50 (IQR = 16), respectively. No significant difference was found between the median ages (Z = 1.317 P = 0.189).

Most common presenting symptoms were neck mass (n = 35; %52.3), hearing loss and ringing or fullness of ears (n = 16; %23.9) and nasal bleeding (n = 12; %17.9). Headache (n = 4; %4.5), blurry and double vision (n = 1; %1.5) were relatively uncommon symptoms. Pathological examination revealed 10.4% (n = 7) having keratinized squamous cell carcinoma (SCC), 32.8% (n = 22) non-keratinized SCC and 56.8% (n = 38) undifferentiated carcinoma. Patients and disease characteristics are shown in [Table 1].
Table 1: Patient and Disease Characteristics: (n=67)

Click here to view


Patients were staged with PET-CT and MRI in 92.5% (n = 62); MRI and Thoracoabdominal CT in 7.4% (n = 5). According to TNM 8th, 4.5% (n = 3) of the cases were stage 1, 16.4% (n = 11) were stage 2, 38.8% (n = 26) were stage 3 and 40.3% (n = 27) were stage 4.

All patients except one (T1N0) received concurrent cisplatin (40 mg/m2) or carboplatin (100 mg/m2) based weekly chemotherapy for median of 6 weeks (range, 3–7). Three patients referred from other facilities received 3 cycles of induction chemotherapy with TPF (cisplatin 75 mg/m2 and docetaxel 75 mg/m2 on day 1, 5-FU 750 mg/m2 on day 1–4 every 3 weeks) and 44 (70%) patients received median 2 (range, 1–3) cycles of adjuvant PF (cisplatin 80 mg/m2 on day 1 and 5-FU 800-1000 mg/m2 on day 1–4 every 3 weeks).

Mean ± 11 Standard Deviation (sd) of D50 of patient's right and left parotid glands and cochleae were 33 ± 11 11 Gy; 31 ± 11 9 Gy and 37 ± 11 14 Gy; 34 ± 11 14 Gy, respectively. Mean ± 11 sd of Dmax of brainstem and medulla spinalis were 51 ± 11 11 Gy and 42 ± 11 12 Gy, respectively. These values were belonged to the first RT plan since all of the patients had at least one adaptive replan.

Patterns of failure and survival data

During the median 51 months (range, 2–100) follow up, 17 patients (29%) died, 12 of them related to disease progression, and toxicity (n = 8 and n = 4). Thirteen patients relapsed (19.4%), six of them (8.9%) recurred locoregionally, and 7 (10.4%) of them developed distant metastasis. The six patients with distant metastasis, 1 with local recurrence, and 1 with regional recurrence died. Acute neutropenia-related toxicity was the cause of death in 3 patients and late pharyngeal bleeding in one. One patient (T4N2) developed a second primary tumor at 32 months follow-up and died at 64 months. One patient (T4N2) had pathologically confirmed mediastinal lymph node recurrence (9th month) had salvage mediastinal RT without systemic therapy, and he was alive at 25 months follow-up. [Table 2] shows the outcome of the loco-regional recurrences. Locoregional relapse-free survival, DFS, DMFS and OS estimates at 2 and 5 years are 83% and 63%, 78.4%, and 61.7%, 83%, and 69%, 86%, and 71%, respectively [Figure 1] and [Figure 2].
Figure 1: Temporal survival patterns of nasopharyngeal cancer patients; overall survival (blue), and disease-free survival (red). The 2- and 5-year overall survival estimate was 86% and %71 and the 2- and 5-year disease free survival was 78.4% and 61.7%, respectively

Click here to view
Figure 2: Temporal survival patterns of nasopharyngeal cancer patients; distant metastasis free survival (blue) and loco-regional recurrence free survival (red). The 2- and 5-year distant metastasis free survival estimate was 83% and 69% and the 2- and 5-year locoregional recurrence free survival was 83% and 63%, respectively

Click here to view
Table 2: Locoregional failures

Click here to view


Toxicity

Acute RT-related side effects were mostly grade 1 or 2 mucositis and dermatitis and resolved within months following RT and chemotherapy. Grade ≥3 dysphagia and mucositis observed in 28 (42%) patients required daily IV fluid transfusion and/or hyperalimentation on the last 2-3 weeks of RT. Three patients (4%) died within 3 months after diagnosis because of neutropenia-related infections (two of them were T3N2, and one of them died after the last weekly chemotherapy, and the other died after the 1st cycle of adjuvant chemotherapy). One patient (T1N2) had grade 4 encephalitis, hospitalized but recovered and free of disease at 27 months follow-up. None of the patients had ≥grade 3 mucous membranes and salivary gland toxicity beyond 6 months. Two patients experienced ≥grade 3 late adverse events; one had grade 3 temporomandibular joint stiffness, and one died because of severe pharyngeal bleeding at 9 months follow up. One patient developed nasal synechia and had repeated surgical interventions.


   Discussion Top


In our study, 67 patients with NPC treated with SIB-IMRT with daily MVCT confirmation were reviewed. Patients received concurrent chemotherapy (n = 66) and either induction (n = 3) or adjuvant systemic therapy (n = 44). During the median 51 months follow-up, estimated 5-year LRRFS, DMFS, and OS rates were 85.7%, 85%, and 71%, respectively, with relatively low acute and late RT-related salivary gland toxicity rates.

Randomized clinical trials have shown benefit in terms of low toxicity and local control with IMRT over 2 and 3-dimensional techniques in locally advanced in NPC.[4],[5] HT is a unique way of IMRT and IGRT combination and can produce highly conformal dose distribution to the compound target volumes. Since it offers a steeper dose gradient, precise delineation, and treatment delivery is extremely important. MRI effectively shows the tumor extension of the structures around the base of the skull, such as brainstem/cranial nerves, and PET-CT helps to determine positive nodal volumes and distant metastasis more accurately.[12],[13] In the present study, the high rate of use of these modalities led to more proper contouring and staging, and the daily use of MVCT allowed more reliable RT delivery.

Despite advanced treatment techniques in NPC, isolated local and regional recurrences still occur either because of intrinsic radioresistance or insufficient dose nearby radiosensitive critical structures. The current treatment options include RT (Brachytherapy, Stereotactic radiosurgery, IMRT), surgery (Nasopharyngectomy, Neck Dissection), and chemotherapy either alone or in different combinations but, the upfront management of this type of failures remains to be determined. A significant proportion of recurrences can be successfully treated with 35%–70% 5-year local-regional control rates, whereas cranial involvement and N3 disease are not present.[14],[15] In our series, 4 of 6 loco-regional relapses were treated with ReRT and/or neck dissection, and obviously, the dosimetric advantage obtained by HT helped to make the optimal reirradiations possible.

Several randomized trials were established the survival advantage of combination RT with chemotherapy over RT alone in locally advanced NPC.[16],[17],[18],[19] The addition of chemotherapy also decreases local, regional, and distant recurrences. We found that except 4 patients, all received a median 6 cycles of weekly platin, and approximately 2/3 of the patients received adjuvant PF. This compares favorably to the compliance rates of another phase 3 randomized trials.[17] Although IMRT with chemotherapy achieves excellent loco-regional control rates, the development of distant organ metastasis still occurs and could not be salvaged and is the main cause of death.[8],[20],[21] In the current study, all patients with DM (n = 7, 10.4%) received concurrent CRT, and 6 of them received additional adjuvant chemotherapy, but all of them except one died at the last follow-up, suggesting the need for more effective systemic therapies. Besides, neutropenia-related severe (≥3) systemic toxicity is a big concern; 3 patients died of sepsis, and one patient developed grade 4 encephalitis.

One of the main expected benefits of the IMRT planning technique is the prevention of excessive doses to the salivary glands, thus limits the severity of xerostomia. Mean ± 11 sd of D50 of parotid glands were 33 ± 11 11 Gy and 31 ± 11 9 Gy, which was quite bit more than other series,[22],[23] but none of our patients experienced severe xerostomia beyond 6 months post-RT. The degree of xerostomia is dependent largely on the dose/volume of the gland in the RT field, accordingly, adaptive IMRT is a good option to spare the parotid glands and limits xerostomia.[10] We believe that despite the high percentage of advanced-stage disease and high mean D50 of parotid glands, severe mucous membrane and salivary gland toxicities were low due to the adaptive IMRT re-plans.

The RTOG 0225 was the first multicenter SIB-IMRT feasibility study, which used a 70 Gy/33 regimen quite similar to the current study to be used as the standard RT of NPC.[8] They reported a 2-year LRFFS as 89.3% with an OS of 80.2%. Other studies documented more comparable results [Table 3], with an 83%-63% LRRFS and %86-71% OS at 2 and 5-year, respectively. The grade 5 toxic events (n = 3) occurred within the 1st 3 months after NPC diagnosis may have led to low rates of LRRFS in our study. Moreover, about 10.5% and 32.8% of the patients in our study were WHO type 1 and type 2, and it is known that undifferentiated carcinomas have higher 5-year survival than those squamous cell carcinomas, which is not correct when considering 10-year survival.[24] This can also explain our early-stage low survival rates.
Table 3: Tomotherapy series

Click here to view


SIB technique offers a relatively high fraction and prescription dose to the tumoral site, and combination with chemotherapy causes increased rates of serious adverse effects. In a study of Bakst et al. prescribed dose was 70 Gy/30 frx, and they reported varying degrees of temporal lobe necrosis in about 12% of patients.[25] Du et al. reported their toxicity outcome in 2 different prescriptions (67.5 Gy/30 frx and 70-74/33 frx to primary tumor and nodes), and they found a 15.9% and 8.4% grade 3 non-hematologic acute toxicity, respectively.[9] Lee et al. documented grade 3 and 4 non-hematologic acute adverse effects in 72% of patients.[8] Toxicity rates were not correlated with each other in different series [Table 3]; the possible reason is the different prescriptions and evaluations by the doctors.


   Conclusions Top


The present study reemphasized that adaptive SIB-IMRT with HT is a good option for the management of NPC with comparable loco-regional control rates and low salivary gland toxicity.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.







[28]



 
   References Top

1.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.  Back to cited text no. 1
    
2.
Turkish cancer statistics database. Department of Cancer Turkish Ministry of Health; 2015. Available from: https://hsgm.saglik.gov.tr/tr/kanser-istatistikleri/yillar/2015-yili-turkiye-kanser-i-statistikleri.html. [Last accessed on 2019 May 09].  Back to cited text no. 2
    
3.
Baujat B, Audry H, Bourhis J, Chan AT, Onat H, Chua DT, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: An individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 2006;64:47-56.  Back to cited text no. 3
    
4.
Peng G, Wang T, Yang KY, Zhang S, Zhang T, Li Q, et al. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiother Oncol 2012;104:286-93.  Back to cited text no. 4
    
5.
Kam MK, Leung SF, Zee B, Chau RM, Suen JJ, Mo F, et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 2007;25:4873-9.  Back to cited text no. 5
    
6.
Dogan N, King S, Emami B, Mohideen N, Mirkovic N, Leybovich LB, et al. Assessment of different IMRT boost delivery methods on target coverage and normal-tissue sparing. Int J Radiat Oncol Biol Phys 2003;57:1480-91.  Back to cited text no. 6
    
7.
Mohan R, Wu Q, Manning M, Schmidt-Ullrich R. Radiobiological considerations in the design of fractionation strategies for intensity-modulated radiation therapy of head and neck cancers. Int J Radiat Oncol Biol Phys 2000;46:619-30.  Back to cited text no. 7
    
8.
Lee N, Harris J, Garden AS, Straube W, Glisson B, Xia P, et al. Intensity- modulated radiation therapy with or without chemotherapy for naso- pharyngeal carcinoma: Radiation Therapy Oncology Group phase II trial 0225. J Clin Oncol 2009;27:3684-90.  Back to cited text no. 8
    
9.
Du L, Zhang XX, Feng LC, Chen J, Yang J, Liu HX, et al. Treatment of nasopharyngeal carcinoma using simultaneously modulated accelerated radiation therapy via helical tomotherapy: A phase 2 study. Radiol Oncol 2016;50:218-25.  Back to cited text no. 9
    
10.
Castelli J, Simon A, Louvel G, Henry O, Chajon E, Nassef M, et al. Impact of head and neck cancer adaptive radiotherapy to spare the parotid glands and decrease the risk of xerostomia. Radiat Oncol 2015;10:6.  Back to cited text no. 10
    
11.
Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341-6.  Back to cited text no. 11
    
12.
Raut AA, Naphade PS, Chawla A. Imaging of skull base: Pictorial essay. Indian J Radiol Imag 2012;22:305-16.  Back to cited text no. 12
    
13.
Castaldi P, Leccisotti L, Bussu F, Miccichè F, Rufini V. Role of (18) F-FDG PET-CT in head and neck squamous cell carcinoma. Acta Otorhinolaryngol Ital 2013;33:1-8.  Back to cited text no. 13
    
14.
Suarez C, Rodrigo PJ, Rinaldo A, Langendijk JA, Shaha AR, Ferlito A. Current treatment options for recurrent nasopharyngeal cancer. Eur Arch Otorhinolaryngol 2010;267:1811-24.  Back to cited text no. 14
    
15.
Lo WC, Wang CP, Ko JY, Lou PJ, Yang TL, Wang CW, et al. Salvage treatment for ısolated regional failure of nasopharyngeal carcinoma after primary radiotherapy. Ann Surg Oncol 2012;19:1001-8.  Back to cited text no. 15
    
16.
Chen QY, Wen YF, Guo L, Liu H, Huang PY, Mo HY, et al. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: Phase III randomized trial. J Natl Cancer Inst 2011;103:1761-70.  Back to cited text no. 16
    
17.
Al-Sarraf M, LeBlanc M, Giri PG, Cooper J, Vuong T, Forastiere AA, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. J Clin Oncol 1998;16:1310-7.  Back to cited text no. 17
    
18.
Chan AT, Leung SF, Ngan RK, Teo PM, Lau WH, Kwan WH, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 2005;97:536-9.  Back to cited text no. 18
    
19.
Wee J, Tan EH, Tai BC, Wong HB, Leong SS, Tan T, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 2005;23:6730-8.  Back to cited text no. 19
    
20.
Kam MK, Teo PM, Chau RM, Cheung KY, Choi PH, Kwan WH, et al. Treatment of nasopharyngeal carcinoma with intensity- modulated radiotherapy: The Hong Kong experience. Int J Radiat Oncol Biol Phys 2004;60:1440-50.  Back to cited text no. 20
    
21.
Shueng PW, Shen BJ, Wu LJ, Liao LJ, Hsiao CH, Lin YC, et al. Concurrent image-guided intensity modulated radiotherapy and chemotherapy following neoadjuvant chemotherapy for locally advanced nasopharyngeal carcinoma. Radiat Oncol 2011;6:95.  Back to cited text no. 21
    
22.
Leung SW, Lee T. Treatment of nasopharyngeal carcinoma by tomotherapy: Five-year experience. Radiat Oncol 2013;8:107.  Back to cited text no. 22
    
23.
Chitapanarux I, Nobnop W, Sripan P, Chumachote A, Tharayichitkul E, Chakrabandhu S, et al. The outcome of the fisrt 100 nasopharengeal cancer patients in Thailand treated by tomotherapy. Radiol Oncol 2017;51:351-6.  Back to cited text no. 23
    
24.
Pryzant RM, Wendt CD, Delclos L, Peters LJ. Re-treatment of nasopharyngeal carcinoma in 53 patients. Int J Radiat Oncol Biol Phys 1992;22:941-7.  Back to cited text no. 24
    
25.
Bakst RL, Lee N, Pfister DG, Zelefsky MJ, Hunt MA, Kraus DH, et al. Hypofractionated dose-painting intensity modulated radiation therapy with chemotherapy for nasopharygeal carcinoma: A prospective trial. Int J Radiat Oncol Biol Phys 2011;80:148-53.  Back to cited text no. 25
    
26.
Ren G, Du L, Ma L, Feng LC, Zhou GX, Qu BL, et al. Clinical observation of 73 nasopharyngeal carcinoma patients treated by helical tomotherapy: The China experience. Technol Cancer Res Treat 2011;10:259-66.  Back to cited text no. 26
    
27.
Du L, Zhang XX, Ma L, Feng LC, Fang L, Zhou G, et al. Clinical study of nasopharyngeal carcinoma treated by helical tomotherapy in China: 5- year outcomes. Biomed Res Int 2014;2014:980767. doi: 10.1155/2014/980767.  Back to cited text no. 27
    
28.
Zhang XX, Du L, Zhao F, Wang Q, Yang S, Ma L, et al. A phase 2 clinical trial of concurrent helical tomotherapy plus cetuximab followed by adjuvant chemotherapy with cisplatin and docetaxel for locally advanced nasopharyngeal carcinoma. Int J Biol Sci 2016;12:446-53.  Back to cited text no. 28
    


    Figures

  [Figure 1], [Figure 2]
 
 
    Tables

  [Table 1], [Table 2], [Table 3]


This article has been cited by
1 Prediction of Changes in Tumor Regression during Radiotherapy for Nasopharyngeal Carcinoma by Using the Computed Tomography-Based Radiomics
Yu Yang, Jiayang Wu, Wenfeng Mai, Hengguo Li, Sorayouth Chumnanvej
Contrast Media & Molecular Imaging. 2022; 2022: 1
[Pubmed] | [DOI]



 

Top
  
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    Abstract
   Introduction
    Materials and Me...
   Results
   Discussion
   Conclusions
    References
    Article Figures
    Article Tables

 Article Access Statistics
    Viewed1600    
    Printed22    
    Emailed0    
    PDF Downloaded266    
    Comments [Add]    
    Cited by others 1    

Recommend this journal